A pioneering clinical trial led by Neuroscience Research Australia has found that intranasal insulin could offer a promising new treatment for delirium, potentially reducing hospital stays for older patients by several days and addressing a significant gap in care.
-
Latest News
Telix Pharmaceuticals lifts revenue guidance after strong third quarter performance
October 15, 2025 -
Latest News
Chimeric and Viral Vector Manufacturing Facility sign advanced manufacturing agreement
October 15, 2025 -
Latest News
Vicki Robinson joins Proteomics International board as independent non-executive director
October 15, 2025
-
Latest News Intranasal insulin delivers new hope for delirium treatment October 15, 2025
-
Latest News Medibank backs expansion of Emyria’s trauma and depression programs to Queensland October 15, 2025Emyria (ASX:EMD) has secured expanded funding support from Medibank Private for patients accessing its treatment-resistant depression and post-traumatic stress disorder programs, marking a significant step in the company’s national growth strategy.
-
AusBiotech Victorian Government Ministers to headline Australia’s biggest biotech week October 14, 2025Senior Victorian Government representatives will headline flagship events at this year’s AusBiotech International Conference 2025 and AusBiotech Invest Conference 2025 in Melbourne, highlighting the state’s growing leadership in biotechnology and life sciences.
-
Latest News Clarity's Co-PSMA trial hits primary endpoint in early prostate cancer detection October 14, 2025A clinical trial led by Professor Louise Emmett at St Vincent’s Hospital, Sydney, has achieved its primary endpoint, showing that 64Cu-SAR-bisPSMA detects significantly more prostate cancer lesions than the current standard-of-care PSMA PET imaging in men with low PSA levels.
-
Latest News Nexsen to list on ASX with rapid, cross-sector diagnostic platform October 13, 2025Melbourne nano-biotech Nexsen (ASX:NXN) will debut on the ASX with its world-first biosensing platform that brings lab-grade diagnostics to the point of need.
-
Latest News Medical Developments International signals a turn to growth as Penthrox momentum builds October 13, 2025Medical Developments International (ASX:MVP) used its 2025 AGM to draw a clear line under its rebuild and set out a confident growth agenda.
-
Latest News PYC Therapeutics readies PYC-002 for clinic after positive pre-clinical data October 13, 2025PYC Therapeutics (ASX:PYC) is advancing its Phelan-McDermid syndrome (PMS) program toward first-in-human studies, reporting non-human primate results that, along with earlier patient-derived neuron data, support progression to the clinic.
-
Latest News Adherium launches early exercise incentive offer to reward optionholders October 13, 2025Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.
-
Latest News Artrya clears key US milestone for coronary device, targets FDA filing by year-end October 13, 2025Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.
-
AusBiotech AusBiotech unveils international conference program for Australia’s biggest week in biotech October 9, 2025The program has been unveiled for the AusBiotech International Conference 2025, confirming the most ambitious lineup in the event’s history, with over 60 sessions and 250 speakers set to gather the global life sciences community in Melbourne from 21 to 24 October at the Melbourne Convention and Exhibition Centre.
-
Latest News CUREator opens major funding round to accelerate early-stage biotech innovation October 8, 2025Australia’s leading life sciences incubator, CUREator, delivered by Brandon BioCatalyst in partnership with CSIRO, has opened applications for a new $33 million BioMedTech Incubator (BMTI) funding round.
-
Latest News Immuron Submits IND to US FDA for novel therapy targeting C. difficile infection October 8, 2025Immuron (ASX:IMC) has submitted an Investigational New Drug application to the US FDA for its proprietary oral therapy IMM-529, marking a significant milestone in the company’s effort to combat one of the world’s most persistent and dangerous bacterial infections.
-
Latest News Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002 October 8, 2025Percheron Therapeutics (ASX:PER) has announced final results from its Phase I clinical trial of HMBD-002, a novel immunotherapy targeting multiple forms of advanced cancer, showing a strong safety profile and early signs of clinical activity.
-
Latest News NeuroScientific gains TGA approval for first patients in Crohn’s disease program October 8, 2025NeuroScientific Biopharmaceuticals (ASX:NSB) has reached a significant milestone in its clinical development program, announcing TGA approval for the first three patients to receive its proprietary stem cell therapy, StemSmart, under Australia’s Special Access Program for the treatment of fistulising Crohn’s disease.
-
Latest News FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial October 8, 2025Neurizon’s Managing Director and CEO, Dr Michael Thurn, described the FDA’s clearance as “a defining moment” for the company’s mission to accelerate access to innovative therapies for people living with ALS.
-
Latest News Cyteph completes recruitment for Phase 1 trial of novel therapy for aggressive brain cancer October 8, 2025Australian biotechnology company Cyteph has announced the completion of recruitment for its first-in-human Phase 1 clinical trial of CYT-101, a groundbreaking off-the-shelf, HLA-matched CMV-specific T cell therapy being developed to treat recurrent glioblastoma multiforme.
-
Latest News Dimerix reports positive outcome from PARASOL collaboration October 8, 2025Dimerix (ASX:DXB) has received final data from the PARASOL collaboration, reinforcing support for the company’s proteinuria-based endpoints in its Phase 3 ACTION3 study for Focal Segmental Glomerulosclerosis.
-
Latest News MTPConnect and Wholesale Investor unite to accelerate investment in life sciences sector October 8, 2025Australia’s Life Sciences Innovation Accelerator, MTPConnect, has announced a landmark strategic partnership with Wholesale Investor, one of the region’s leading private capital marketplaces, to help bridge the country’s most persistent gap in the commercialisation pipeline.
-
AusBiotech AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector October 7, 2025AusBiotech has released its 2024–25 Annual Report, marking what Chair Dr James Campbell described as a “transformational and defining year” for the organisation and Australia’s broader life sciences community.
-
AusBiotech AusPartnering - where connections drive discovery at Australia’s biggest week in biotech October 7, 2025The countdown is on to Australia’s biggest week in biotechnology, and with it comes a unique opportunity to forge connections that could shape the future of health and innovation.
-
Latest News AusBiotech welcomes $13.6 million investment to strengthen clinical trials October 6, 2025AusBiotech CEO Rebekah Cassidy said the organisation applauds the government’s commitment to reform, describing it as a “once-in-a-generation opportunity” to secure Australia’s global leadership in clinical research.
New Stories
-
Chimeric and Viral Vector Manufacturing Facility sign advanced manufacturing agreement
October 15, 2025 - - Latest News -
Medibank backs expansion of Emyria’s trauma and depression programs to Queensland
October 15, 2025 - - Latest News -
Vicki Robinson joins Proteomics International board as independent non-executive director
October 15, 2025 - - Latest News -
Telix Pharmaceuticals lifts revenue guidance after strong third quarter performance
October 15, 2025 - - Latest News -
Intranasal insulin delivers new hope for delirium treatment
October 15, 2025 - - Latest News -
Victorian Government Ministers to headline Australia’s biggest biotech week
October 14, 2025 - - AusBiotech -
Clarity's Co-PSMA trial hits primary endpoint in early prostate cancer detection
October 14, 2025 - - Latest News